Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 120 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2016', provides in depth analysis on Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted pipeline therapeutics. 

The report provides comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) 
- The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) Overview 9
Therapeutics Development 10
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Products under Development by Stage of Development 10
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Products under Development by Therapy Area 11
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Products under Development by Indication 12
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Products under Development by Companies 16
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Products under Development by Universities/Institutes 22
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Assessment 24
Assessment by Monotherapy/Combination Products 24
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development 30
AbbVie Inc 30
American Gene Technologies International Inc. 31
AstraZeneca Plc 32
BeiGene, Ltd. 33
Clovis Oncology, Inc. 34
Eisai Co., Ltd. 35
Hager Biosciences, LLC 36
IMPACT Therapeutics, Inc. 37
Jeil Pharmaceutical Co., Ltd. 38
Jiangsu Hengrui Medicine Co., Ltd. 39
Mitsubishi Tanabe Pharma Corporation 40
Nerviano Medical Sciences S.r.l. 41
Takeda Pharmaceutical Company Limited 42
Tesaro, Inc. 43
Teva Pharmaceutical Industries Ltd. 44
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Drug Profiles 45
ABT-767 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
AG-PD - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
AZ-0108 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AZD-1775 + olaparib - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
BGB-290 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CK-102 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
E-7449 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
fluzoparib - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
IMP-04297 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
JPI-289 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
MP-124 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
niraparib - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
NMSP-118 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
NMSP-648 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
NMSP-914 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
olaparib - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
R-554 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
rucaparib camsylate - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
SC-10914 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Small Molecule to Inhibit PARP-1 for Undisclosed Indication - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecules to Inhibit PARP-1 for Colorectal Cancer - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
veliparib - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
XZ-120312 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
YHP-743 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Dormant Projects 98
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Discontinued Products 103
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Featured News & Press Releases 104
Oct 26, 2016: Lynparza Phase III SOLO-2 trial shows significant progression-free survival benefit 104
Oct 26, 2016: Myriad's BRACAnalysis CDx Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib 104
Oct 08, 2016: DNA Repair-Blocking Drug Substantially Improves Progression Free survival for Common Form of Recurrent Ovarian Cancer, International Trial Finds 105
Oct 08, 2016: Myriad's myChoice HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib 106
Oct 08, 2016: TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016 107
Oct 07, 2016: Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress 109
Sep 28, 2016: Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress 112
Sep 12, 2016: TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission 112
Sep 06, 2016: TESARO To Present Phase 3 Results From ENGOT-OV16/NOVA Trial of Niraparib at the 2016 European Society for Medical Oncology Annual Meeting 113
Sep 05, 2016: A Gene Defect as a Potential Gateway for Targeted Prostate Cancer Therapy 113
Aug 23, 2016: FDA Accepts Clovis Oncology's New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer 114
Jul 08, 2016: ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial 115
Jul 08, 2016: Loyola Oncologist Co-authors Veliparib plus Carboplatin Study That Used New, Targeted Model to Test Breast Cancer Treatment 117
Jun 29, 2016: Myriad myChoice HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO Pivotal Phase 3 Ovarian Cancer Study with Niraparib 118
Appendix 119
Methodology 119
Coverage 119
Secondary Research 119
Primary Research 119
Expert Panel Validation 119
Contact Us 119
Disclaimer 120

List of Tables

Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Products under Development by Companies, H2 2016 (Contd..2) 19
Products under Development by Companies, H2 2016 (Contd..3) 20
Products under Development by Companies, H2 2016 (Contd..4) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Products under Investigation by Universities/Institutes, H2 2016 23
Assessment by Monotherapy/Combination Products, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Pipeline by AbbVie Inc, H2 2016 30
Pipeline by American Gene Technologies International Inc., H2 2016 31
Pipeline by AstraZeneca Plc, H2 2016 32
Pipeline by BeiGene, Ltd., H2 2016 33
Pipeline by Clovis Oncology, Inc., H2 2016 34
Pipeline by Eisai Co., Ltd., H2 2016 35
Pipeline by Hager Biosciences, LLC, H2 2016 36
Pipeline by IMPACT Therapeutics, Inc., H2 2016 37
Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 38
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 39
Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 40
Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 41
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 42
Pipeline by Tesaro, Inc., H2 2016 43
Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 44
Dormant Projects, H2 2016 98
Dormant Projects (Contd..1), H2 2016 99
Dormant Projects (Contd..2), H2 2016 100
Dormant Projects (Contd..3), H2 2016 101
Dormant Projects (Contd..4), H2 2016 102
Discontinued Products, H2 2016 103